Last week, Andrew J. Armstrong, MD, MSc, lead researcher of the phase 3 ARCHES trial, spoke with i3 Health about the recent approval of enzalutamide (Xtandi®, Astellas Pharma Inc.) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and the variety of options that are now available for the treatment of metastatic hormone-sensitive disease. In this second installment, Dr. Armstrong discusses the ongoing evolution of therapeutic strategies in mCSPC and shares his advice fo...

The FDA has now approved olaparib (Lynparza®, AstraZeneca) for the maintenance treatment of adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma who have not experienced disease progression after at least 16 weeks of a first-line platinum-based chemotherapy regimen. In addition, the FDA approved the BRACAnalysis CDx test (Myriad Genetic Laboratories, Inc.) as a companion diagnostic for the selection of patients with deleterious or suspected ...

The FDA has now approved enzalutamide (Xtandi®, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC).Patients with mCSPC, who comprise up to 5% of US patients with prostate cancer, have metastatic disease and either have not yet received or are continuing to respond to hormone therapy. Androgen deprivation therapy (ADT) has been considered the standard of care for mCSPC. After experiencing an initial treatment response, most patients who receive ADT alo...

Adding daratumumab to bortezomib/melphalan/prednisone (VMP) increases overall survival in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), according to results of the phase 3 ALCYONE trial to be presented in December at the American Society of Hematology (ASH) Annual Meeting and Exposition.Patients who are ineligible for autologous stem cell transplantation comprise approximately half of NDMM patients, and the combination of bortezomib, a proteasome inhibitor, with me...

​In previously untreated chronic lymphocytic leukemia (CLL), acalabrutinib (Calquence®, AstraZeneca) improves progression-free survival either as monotherapy or in combination with obinutuzumab (Gazyva®, Genentech), according to interim results of the phase 3 ELEVATE-TN trial to be presented at the American Society of Hematology (ASH) Annual Meeting.Acalabrutinib, a highly selective, covalent irreversible Bruton tyrosine kinase inhibitor, is currently FDA approved for the treatment of relapsed o...